PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7341636-8 1980 The significant increases in MAO specific activity seen in heart and kidney following L-DOPA treatment could be reduced or prevented by benserazide. Levodopa 86-92 monoamine oxidase A Rattus norvegicus 29-32 3670563-3 1987 A dose-dependent and often complete blockade of all three signs was obtained with L-DOPA plus carbidopa (10:1) as well as with other classes of pharmacological agents that are used in the treatment of Parkinson"s disease, i.e. direct or indirect dopamine (DA) agonists (amantadine, pergolide, lisuride) and inhibitors of monoamine oxidase (MAO) (clorgyline, pargyline, deprenyl, tranylcypromine). Levodopa 82-88 monoamine oxidase A Rattus norvegicus 321-338 3670563-3 1987 A dose-dependent and often complete blockade of all three signs was obtained with L-DOPA plus carbidopa (10:1) as well as with other classes of pharmacological agents that are used in the treatment of Parkinson"s disease, i.e. direct or indirect dopamine (DA) agonists (amantadine, pergolide, lisuride) and inhibitors of monoamine oxidase (MAO) (clorgyline, pargyline, deprenyl, tranylcypromine). Levodopa 82-88 monoamine oxidase A Rattus norvegicus 340-343 3668521-3 1987 The response of MAO-inhibited rats to L-dopa contrasted sharply with those not treated with the MAO inhibitor; the latter showed no change in NE, NMN and 3-MT after similar administration of L-dopa. Levodopa 38-44 monoamine oxidase A Rattus norvegicus 16-19 3930664-3 1985 However, in rats previously treated with the MAO inhibitors pargyline or tranylcypromine, the same L-DOPA or free DA treatment resulted in significant increases in both 3-MT and DA sulfate in the hypothalamus, brainstem, and striatum. Levodopa 99-105 monoamine oxidase A Rattus norvegicus 45-48 7341636-0 1980 The influence of benserazide on changes in monoamine oxidase activity in some rat tissues following treatment with L-DOPA. Levodopa 115-121 monoamine oxidase A Rattus norvegicus 43-60 2960778-5 1987 Thus inhibition of COMT, like inhibition of MAO, is able to enhance the central effects of L-dopa. Levodopa 91-97 monoamine oxidase A Rattus norvegicus 44-47 3082400-2 1986 In rats bearing unilateral 6-hydroxydopamine lesions of the nigro-striatal dopamine pathways, both MDL 72145 and clorgyline, a selective inhibitor of MAO A, augmented the contralateral turning response to L-DOPA combined with carbidopa. Levodopa 205-211 monoamine oxidase A Rattus norvegicus 150-155 7341636-14 1980 It is concluded that L-DOPA increases the specific activity of MAO-A in rat heart and kidney as a result of its decarboxylation. Levodopa 21-27 monoamine oxidase A Rattus norvegicus 63-68 44325-7 1979 MAO inhibitor resulted in a vast accumulation of L-dopa: e.g. (1) L-5HTP was more slowly eliminated, and (2) 5-HT blockers produced a decreased content of 5-HT after injection of L-5HTP, in contrast to the finding that DA-blockers produced an incresed content of DA after injection of L-dopa. Levodopa 49-55 monoamine oxidase A Rattus norvegicus 0-3 44547-3 1979 Cerebral PLP concentrations were reduced after some of these treatments, notably injection of ethanol, or L-dopa alone or with beta-phenylisopropylhydrazine, an inhibitor of MAO, or of 5-HTP together with N-[beta-(chlorophenoxy)ethyl]cyclopropylamine hydrochloride, Lilly 51641, another MAO inhibitor. Levodopa 106-112 monoamine oxidase A Rattus norvegicus 174-177 44547-3 1979 Cerebral PLP concentrations were reduced after some of these treatments, notably injection of ethanol, or L-dopa alone or with beta-phenylisopropylhydrazine, an inhibitor of MAO, or of 5-HTP together with N-[beta-(chlorophenoxy)ethyl]cyclopropylamine hydrochloride, Lilly 51641, another MAO inhibitor. Levodopa 106-112 monoamine oxidase A Rattus norvegicus 287-290 44325-7 1979 MAO inhibitor resulted in a vast accumulation of L-dopa: e.g. (1) L-5HTP was more slowly eliminated, and (2) 5-HT blockers produced a decreased content of 5-HT after injection of L-5HTP, in contrast to the finding that DA-blockers produced an incresed content of DA after injection of L-dopa. Levodopa 285-291 monoamine oxidase A Rattus norvegicus 0-3 918143-0 1977 MAO activity in rat brain stem and cerebral cortex following acute and chronic treatment with L-dopa and ethanol + L-dopa. Levodopa 94-100 monoamine oxidase A Rattus norvegicus 0-3 918143-0 1977 MAO activity in rat brain stem and cerebral cortex following acute and chronic treatment with L-dopa and ethanol + L-dopa. Levodopa 115-121 monoamine oxidase A Rattus norvegicus 0-3 918143-1 1977 This work reports the effects of acute and chronic administration of L-dopa and ethanol + L-dopa on MAO activity in rat brain stem and cerebral cortex using noradrenaline (NA), dopamine (DA), serotonin (5-HT) and tryptamine (Try) as substrates. Levodopa 69-75 monoamine oxidase A Rattus norvegicus 100-103 918143-1 1977 This work reports the effects of acute and chronic administration of L-dopa and ethanol + L-dopa on MAO activity in rat brain stem and cerebral cortex using noradrenaline (NA), dopamine (DA), serotonin (5-HT) and tryptamine (Try) as substrates. Levodopa 90-96 monoamine oxidase A Rattus norvegicus 100-103 23992249-10 2013 CONCLUSIONS AND IMPLICATIONS: In striatum devoid of dopaminergic and serotonergic inputs, most deamination of L-DOPA-derived DA is mediated by MAO-A in MSN and a smaller amount by MAO-B in both MSN and glia. Levodopa 110-116 monoamine oxidase A Rattus norvegicus 143-148 26319690-7 2015 In L-DOPA-treated group, 7-NI significantly enhanced the L-DOPA-derived tissue DA content in this system and decreased the level of the intracellular DA metabolite DOPAC produced by monoamine oxidase (MAO). Levodopa 3-9 monoamine oxidase A Rattus norvegicus 182-199 26319690-7 2015 In L-DOPA-treated group, 7-NI significantly enhanced the L-DOPA-derived tissue DA content in this system and decreased the level of the intracellular DA metabolite DOPAC produced by monoamine oxidase (MAO). Levodopa 3-9 monoamine oxidase A Rattus norvegicus 201-204 26319690-9 2015 It means that the differences in 7-NI and L-NAME-mediated modulation of L-DOPA-induced behavioral and biochemical effects resulted not only from the inhibition of NOS activity but also from differences in their ability to inhibit MAO. Levodopa 72-78 monoamine oxidase A Rattus norvegicus 230-233 23992249-0 2013 Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation. Levodopa 10-16 monoamine oxidase A Rattus norvegicus 54-59 23196068-10 2013 The MAO inhibitor, pargyline, also attenuated cell death and ROS after l-dopa treatment. Levodopa 71-77 monoamine oxidase A Rattus norvegicus 4-7 12711835-18 2003 Quercetin through its COMT and MAO enzyme-inhibiting properties might potentiate the anticatatonic effect of L-dopa plus carbidopa treatment. Levodopa 109-115 monoamine oxidase A Rattus norvegicus 31-34 14743456-2 2004 In this study, male Sprague-Dawley rats were treated with levodopa (L-dopa)-benserazide, which increases DOPAL production by MAO, and disulfiram, an irreversible inhibitor of ALDH, which reduces the formation of DOPAC from DOPAL. Levodopa 58-66 monoamine oxidase A Rattus norvegicus 125-128 14743456-2 2004 In this study, male Sprague-Dawley rats were treated with levodopa (L-dopa)-benserazide, which increases DOPAL production by MAO, and disulfiram, an irreversible inhibitor of ALDH, which reduces the formation of DOPAC from DOPAL. Levodopa 68-74 monoamine oxidase A Rattus norvegicus 125-128 12907313-2 2003 Application of L-DOPA (30 microM) to vas deferens increased basal NA efflux but not electrical field stimulation-evoked release of NA when the tissue was pretreated with an inhibitor of MAO-B (clorgyline 1 microM) or an inhibitor of MAO-A and MOA-B (AGN-1133 1 microM). Levodopa 15-21 monoamine oxidase A Rattus norvegicus 233-238 8813364-6 1996 These findings suggest that the newly produced dopamine from L-DOPA in serotonin neurons of the rat DR is degraded by endogenous MAO. Levodopa 61-67 monoamine oxidase A Rattus norvegicus 129-132 9489509-8 1998 In conclusion, the results presented here confirm the presence of both MAO-A and MAO-B activity in renal tubular epithelial cells, that MAO-A is the predominant enzyme involved in the deamination of the natriuretic hormone dopamine and that the deamination of newly-formed dopamine is a time-dependent process which occurs early after the decarboxylation of L-DOPA. Levodopa 358-364 monoamine oxidase A Rattus norvegicus 136-141 9444560-0 1997 Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior. Levodopa 86-92 monoamine oxidase A Rattus norvegicus 10-71 9444560-6 1997 MAO-A inhibition in conjunction with MAO-B inhibition prolonged the duration of L-DOPA-induced turning but had no effect on the number of turns. Levodopa 80-86 monoamine oxidase A Rattus norvegicus 0-5 11331406-5 2001 Our results indicate that overexpression of the vesicular monoamine transporter and monoamine oxidase A-induced protection against intracellular dopamine toxicity, and conversely that pharmacological inhibition of these pathways potentiated L-DOPA toxicity in catecholaminergic PC12 cells. Levodopa 241-247 monoamine oxidase A Rattus norvegicus 84-103 9585355-1 1998 From using in vitro intracellular recordings from mesencephalic neurons and monoamine-depleted rats, we report that the functions of levodopa in the brain are greatly enhanced and prolonged by high doses of the monoamine oxidase (MAO) inhibitor deprenyl. Levodopa 133-141 monoamine oxidase A Rattus norvegicus 211-228 9585355-1 1998 From using in vitro intracellular recordings from mesencephalic neurons and monoamine-depleted rats, we report that the functions of levodopa in the brain are greatly enhanced and prolonged by high doses of the monoamine oxidase (MAO) inhibitor deprenyl. Levodopa 133-141 monoamine oxidase A Rattus norvegicus 230-233 9585355-5 1998 The great increase in levodopa responses by deprenyl suggests a likely therapeutic use of this dopamine precursor with a higher dosage of the MAO inhibitor, to reduce effectively the daily levodopa requirements in Parkinson"s disease patients. Levodopa 22-30 monoamine oxidase A Rattus norvegicus 142-145 8976015-9 1996 CONCLUSIONS: This study has shown a high turnover of L-DOPA in the rat pancreas, which can be modulated to give enhanced levels of DOPAC or dopamine by COMT and MAO inhibition. Levodopa 53-59 monoamine oxidase A Rattus norvegicus 161-164 8813364-0 1996 Dopamine produced from L-DOPA is degraded by endogenous monoamine oxidase in neurons of the dorsal raphe nucleus of the rat: an immunohistochemical study. Levodopa 23-29 monoamine oxidase A Rattus norvegicus 56-73 8813364-1 1996 The aim of the present study is to examine by immunohistochemistry whether dopamine produced from L-DOPA in serotonin neurons of the rat brain is degraded by endogenous monoamine oxidase (MAO). Levodopa 98-104 monoamine oxidase A Rattus norvegicus 169-186 8813364-1 1996 The aim of the present study is to examine by immunohistochemistry whether dopamine produced from L-DOPA in serotonin neurons of the rat brain is degraded by endogenous monoamine oxidase (MAO). Levodopa 98-104 monoamine oxidase A Rattus norvegicus 188-191 8813364-3 1996 In L-DOPA/carbidopa-injected rats that were pretreated with an intraperitoneal injection of a MAO inhibitor, pargyline, when compared with the L-DOPA/carbidopa-injected rats without the pargyline pretreatment, neurons of the cluster of the DR became much darker in dopamine staining. Levodopa 3-9 monoamine oxidase A Rattus norvegicus 94-97 7893380-0 1994 Effect of a selective MAO-A inhibitor (Ro 41-1049) on striatal L-dopa and dopamine metabolism: an in vivo study. Levodopa 63-69 monoamine oxidase A Rattus norvegicus 22-27 7643100-0 1995 Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. Levodopa 88-94 monoamine oxidase A Rattus norvegicus 37-56 9620056-0 1995 In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism. Levodopa 82-88 monoamine oxidase A Rattus norvegicus 51-56 9620056-3 1995 Extracellular levels of dopamine were enhanced and DA metabolite levels strongly inhibited both under basal conditions and following L-DOPA administration by pretreatment with the nonselective MAO inhibitor pargyline and the MAO-A selective inhibitors clorgyline and Ro 41-1049. Levodopa 133-139 monoamine oxidase A Rattus norvegicus 225-230 9620056-7 1995 In contrast, both MAO-A and MAO-B mediate DA formation when L-DOPA is administered exogenously. Levodopa 60-66 monoamine oxidase A Rattus norvegicus 18-23 7900446-3 1994 It is suggested that a decrease in MAO activity after madapar cessation may be responsible for dyskinesia arising after cessation of L-DOPA preparations treatment. Levodopa 133-139 monoamine oxidase A Rattus norvegicus 35-38 7874502-10 1994 These results suggest that the reduced striatal DA peak in the gliotic striatum after L-dopa administration was due to accelerated DA catabolism through enhanced MAO activity. Levodopa 86-92 monoamine oxidase A Rattus norvegicus 162-165 7839669-3 1994 It may be suggested that madopare withdrawal-induced decreases in MAO activity might be, to a certain extent, a cause of dyskinesias occurring after discontinuation of L-DOPA drugs. Levodopa 168-174 monoamine oxidase A Rattus norvegicus 66-69 8207420-0 1994 L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. Levodopa 0-28 monoamine oxidase A Rattus norvegicus 140-159 8207420-10 1994 The present findings indicate that deamination by monoamine oxidase A is the primary mechanism for catabolism of striatal dopamine, both under basal conditions and after administration of exogenous L-DOPA. Levodopa 198-204 monoamine oxidase A Rattus norvegicus 50-69 8075859-16 1994 In conclusion, the present results show that both L-DOPA and GluDOPA give origin to substantial amounts of dopamine and the newly-formed amine undergoes considerable deamination to DOPAC.However, dopamine originating from GluDOPA was less deaminated than that resulting from L-DOPA;it appears that this different behaviour may concern aspects related to the formation of the amine and also those related to its deamination and disposition, namely the processes involved in the access of newly-formed dopamine to MAO. Levodopa 50-56 monoamine oxidase A Rattus norvegicus 512-515 7893380-4 1994 We conclude that inhibition of central MAO-A activity promotes synaptic accumulation of dopamine following administration of pharmacological doses of L-dopa. Levodopa 150-156 monoamine oxidase A Rattus norvegicus 39-44 1766471-9 1991 All three COMT inhibitors decreased high 3-OMD levels evoked by MAO inhibitors (+ levodopa/carbidopa). Levodopa 82-90 monoamine oxidase A Rattus norvegicus 64-67 2106792-6 1990 3,4-Dihydroxyphenylacetic acid (DOPAC) is detectable in the adrenal cortex but not in the adrenal medulla, and DOPAC levels increased significantly after L-dopa, which indicates monoamine oxidase (MAO) activity within the adrenal cortex. Levodopa 154-160 monoamine oxidase A Rattus norvegicus 178-195 2124622-6 1990 It is concluded that both MAO-A and MAO-B are important in the metabolism of newly formed DA in kidney slices incubated with exogenous L-dopa. Levodopa 135-141 monoamine oxidase A Rattus norvegicus 26-31 2106792-6 1990 3,4-Dihydroxyphenylacetic acid (DOPAC) is detectable in the adrenal cortex but not in the adrenal medulla, and DOPAC levels increased significantly after L-dopa, which indicates monoamine oxidase (MAO) activity within the adrenal cortex. Levodopa 154-160 monoamine oxidase A Rattus norvegicus 197-200 2113389-12 1990 In these animals levodopa/carbidopa increased brain L-dopa 2.4-4-fold, those of 3-OMD 1.2-1.7-fold compared to intact animals, but the synthesis and metabolism of dopamine and the effects of COMT and MAO inhibitors were not significantly changed. Levodopa 17-25 monoamine oxidase A Rattus norvegicus 200-203 2089083-5 1990 It is concluded that both MAO-A and MAO-B are important in the metabolism of newly-formed dopamine in kidney slices incubated with exogenous L-DOPA. Levodopa 141-147 monoamine oxidase A Rattus norvegicus 26-31